Projected Impact and Cost-Effectiveness of Novel Molecular Blood-Based or Stool-Based Screening Tests for Colorectal Cancer.

ABSTRACT:

Background

Cell-free DNA blood tests (cf-bDNA) and next-generation stool tests could change colorectal cancer (CRC) screening.

Objective

To estimate the clinical and economic impacts of novel CRC screening tests.

Design

Cost-effectiveness analysis using MOSAIC (Model of Screening and Surveillance for Colorectal Cancer).

Data sources

Published data.

Target population

Average-risk persons.

Time horizon

Ages 45 to 100 years.

Perspective

Health sector.

Intervention

Novel versus established CRC screening tests.

Outcome measures

Incidence and mortality of CRC, quality-adjusted life-years (QALYs), costs.

Results of base-case analysis

For colonoscopy every 10 years, annual fecal immunochemical test (FIT), and triennial next-gen

SUBMITTER: Ladabaum U 

PROVIDER: S-EPMC12302969 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature